Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GABRE | P78334 | 1/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL454098 | 0.84 | ALDH1A1 (0.48) | NTRK1NTRK2GAA | |
| SCHEMBL5385127 | 0.83 | CA12 (0.38) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL336391 | 0.82 | MAPK1 (0.50) | GABRA5CA12CA1CA2CA9 | |
| SCHEMBL29565227 | 0.82 | MAPK1 (0.50) | GABRA5CA12CA1CA2CA9 | |
| SCHEMBL23873699 | 0.82 | STAT3 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2132762 | 0.81 | GABRG2 (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2215365 | 0.81 | HTT (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21702362 | 0.81 | TDP1 (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30047650 | 0.81 | TDP1 (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL25209840 | 0.79 | GABRG2 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4445900-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4440702-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118369325-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-2638042-B1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8754096-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-06-17 | — | — | US | disclosed |
| WO-2013169563-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-2654423-A1 | FUSED HETEROCYCLIC AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130267541-A1 | FUSED HETEROCYCLIC AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-10-10 | — | — | US | disclosed |
| US-8481556-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Merck, Sharp & Dohms, Corp. (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2013066360-A1 | FUSED HETEROCYCLIC AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | GABRA1 175/4885GABRG2 336/4885GABRB3 203/4885 |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | GABRA1 4318/4885GABRG2 4028/4885GABRB3 4076/4885 |
| US-20130267541-A1 | FUSED HETEROCYCLIC AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS | CALCR, CALCRL, CNR2 | GABRA1 208/4885GABRG2 325/4885GABRB3 174/4885 |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | GABRA1 175/4885GABRG2 336/4885GABRB3 203/4885 |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | GABRA1 4275/4885GABRG2 4076/4885GABRB3 3919/4885 |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | CD4, HAVCR2, MAVS | GABRA1 4318/4885GABRG2 4028/4885GABRB3 4076/4885 |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | GABRA1 175/4885GABRG2 336/4885GABRB3 203/4885 |
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | GABRA1 4318/4885GABRG2 4028/4885GABRB3 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.